Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells

dc.date.accessioned	2023-03-06T07:33:21Z
dc.date.available	2023-03-06T07:33:21Z
dc.date.issued	2022
dc.identifier.citation	Cell Signal. 2022 Mar;91:110229. doi: 10.1016/j.cellsig.2021.110229. Epub 2021 Dec 24.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100607
dc.relation.isversionof	10.1016/j.cellsig.2021.110229
dc.relation.isversionof	10.1016/j.cellsig.2021.110229
dc.title	Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells
dc.relation.journal	Cell Signal
dc.identifier.doi	10.1016/j.cellsig.2021.110229
dc.contributor.author	Guney Eskiler G
dc.contributor.author	Guney Eskiler G
dc.contributor.author	Ozturk M.